HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilo...
Havn Life Sciences reported revenue of $276,473 for fiscal year 2022, and net income of -$22.44 million. In Q3 2023 (the quarter ended January 31, 2023) revenue was -$12,060, down 152.4% from a year before.
Figures from company filings; latest fiscal year ended April 30, 2022.
No profile data available.